No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
CN Stock MarketDetailed Quotes
600436 Zhangzhou Pientzehuang Pharmaceutical
- 202.00
- -0.50-0.25%
Market to Open Jul 8 09:30 CST
121.87BMarket Cap40.59P/E (TTM)
202.00High202.00Low115lotVolume202.00Open202.50Pre Close2.32MTurnover0.00%Turnover Ratio43.56P/E (Static)603.32MShares296.1852wk High9.42P/B121.87BFloat Cap178.3752wk Low222.75Limit Up603.32MShs Float487.10Historical High182.25Limit Down0.00%Amplitude-6.18Historical Low2.32Dividend TTM202.00Avg Price0lotAsk1.15%Div YieldTTM100Lot Size0lotBid
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
No Data
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Pientzehuang Pharmaceutical Gets Nod to Trails Lymphoma Drug
Zhangzhou Pientzehuang Pharmaceutical (SHA:600436) will conduct clinical trials on PZH2113 capsules after receiving approval from China's National Medical Products Administration, the company said in
Estimating The Fair Value Of Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436)
Key Insights Zhangzhou Pientzehuang Pharmaceutical's estimated fair value is CN¥224 based on 2 Stage Free Cash Flow to Equity With CN¥213 share price, Zhangzhou Pientzehuang Pharmaceutical appears t
Zhangzhou Pientzehuang Pharmaceutical (600436.SH): received the "Drug Clinical Trial Approval Notice" for PZH2113 capsule.
On June 20th, Gelonhui announced that it had received the Approval Notice for Clinical Trials of PZH2113 Capsule, a new drug for chemical drugs of type 1 innovative drugs with independent intellectual property rights. The company still needs to conduct clinical trials and obtain approval from the National Medical Products Administration before it can be produced and launched. This drug is mainly used for the treatment of relapsed/refractory non-Hodgkin's lymphoma, mainly diffuse large B-cell lymphoma. According to the relevant registration regulations for innovative drugs of type 1 in the new registration classification of chemical drugs, the company has completed the P.
Is It Smart To Buy Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) Before It Goes Ex-Dividend?
Readers hoping to buy Zhangzhou Pientzehuang Pharmaceutical., Ltd (SHSE:600436) for its dividend will need to make their move shortly, as the stock is about to trade ex-dividend. The ex-dividend date
600436.SH () 2023 equity distribution: 2.32 yuan per share, share registration on June 6
Pien Tsai (600436.SH) issued the 2023 equity distribution implementation notice. The current profit distribution is based on the plan...
Zhangzhou Pientzehuang Pharmaceutical., Ltd's (SHSE:600436) Stock Has Fared Decently: Is the Market Following Strong Financials?
Most readers would already know that Zhangzhou Pientzehuang Pharmaceutical's (SHSE:600436) stock increased by 4.4% over the past three months. Given its impressive performance, we decided to study t
Comments
Despite a recent drop, Zhangzhou Pientzehuang Pharmaceutical's long-term returns remain impressive. The market sentiment remains steady, reflecting the EPS growth. The current sell-off could be an opportunity if sustainable growth continues.
Zhangzhou Pientzehuang Pharmaceutical (SHSE:600436) Shareholders Have Earned a 17% CAGR Over the Last Five YearsZhangzhou Pientzehuang Pharmaceutical's performance is commendable, with efficient reinvestment of its earnings leading to impressive earnings growth. The company's earnings growth is expected to continue at a similar rate, according to analyst forecasts.
Zhangzhou Pientzehuang Pharmaceutical investors remain upbeat despite high P/E ratio. However, comfort is wavering due to the difficulty of justifying these prices long-term without substantial growth rate improvements.
Zhangzhou Pientzehuang Pharmaceutical's share price reflects steady EPS growth indicating investor sentiment continuity. It appears that shareholders are rewarded generously via dividends, as suggested by total shareholder returns exceeding share price return.
Read more
Analysis
Price Target
No Data
Heat List
CN
Overall
Symbol
Latest Price
%Chg